KAFOCIN
LOE ApproachingNDAORALCAPSULE
Approved
Jun 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KAFOCIN is an oral small-molecule capsule approved by Eli Lilly in 1970 as an NDA product. The mechanism of action, pharmacologic class, and specific indications are not publicly disclosed in available data. Patient population and therapeutic use cannot be determined without additional clinical information.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand team likely focused on lifecycle extension or transition management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KAFOCIN currently shows zero linked job openings, reflecting its mature and declining lifecycle stage. Working on this legacy product offers stability but limited growth opportunity; career advancement depends on company-wide transitions or portfolio rotation.
Brand ManagerField Sales Representative
Worked on KAFOCIN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.